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Atria and ventricles exhibit distinct molecular profiles
that produce structural and functional differences
between the two cardiac compartments. However,
the factors that determine these differences remain
largely undefined. Cardiomyocyte-specific COUP-
TFII ablation produces ventricularized atria that
exhibit ventricle-like action potentials, increased car-
diomyocyte size, and development of extensive T
tubules. Changes in atrial characteristics are accom-
panied by alterations of 2,584 genes, of which 81%
were differentially expressed between atria and
ventricles, suggesting that a major function of
myocardial COUP-TFII is to determine atrial identity.
Chromatin immunoprecipitation assays using E13.5
atria identified classic atrial-ventricular identity
genes Tbx5, Hey2, Irx4, MLC2v, MLC2a, and
MLC1a, among many other cardiac genes, as poten-
tial COUP-TFII direct targets. Collectively, our results
reveal that COUP-TFII confers atrial identity through
direct binding and by modulating expression of a
broad spectrum of genes that have an impact on
atrial development and function.
INTRODUCTION
Atria and ventricles display distinct gene expression profiles that
consist of thousands of differentially expressed genes (Barth
et al., 2005; McGrath and de Bold, 2009; Tabibiazar et al.,
2003). The distinct profiles not only reflect the unique chamber
identities but also serve as the basis to create profound differ-
ences in structural properties, electric activation, excitation-
contraction coupling, and neurohormonal functions between
the two cardiac compartments (de Bold et al., 1981; Ng et al.,
2010). As a result, the ventricles consist of more mitochondria
and an extensive transverse tubule (T tubule) system to provide
energy and calcium flux for force generation, whereas the atria
have more Golgi complexes and endoplasmic reticulum for theirDeveroles as source and target of neurohormonal signaling (Barth
et al., 2005; McGrath and de Bold, 2009; Tabibiazar et al., 2003).
Atrial and ventricular cardiomyocytes develop their unique
identities at an early embryonic stage, partly through regulation
of the expression of distinct genes in each chamber by transcrip-
tion factors such as Tbx5, Hey2, and Irx4 (Bao et al., 1999; Bru-
neau et al., 2001a, 2001b; Evans et al., 2010; Koibuchi and Chin,
2007; Xin et al., 2007). Tbx5 promotes the expression of both
atrial natriuretic factor (Nppa) and connexin 40 (Gja5) that are
preferentially expressed in the atria (Bruneau et al., 2001b;
Mori et al., 2006). In contrast, Irx4 promotes expression of ven-
tricular genes Hand1 and Hand2 and suppresses the atrial re-
porter SmyHC3-HAP (Bao et al., 1999; Bruneau et al., 2001a).
Although Irx4 is important for the regulation of ventricular genes,
it is not sufficient to confer ventricular identity (Bruneau et al.,
2001a). The ventricular Hey2 is known to maintain ventricular
identity by suppressing the atrial genes Myl4 (MLC1a), Myl7
(MLC2a), Sacrolipin (Sln), Gja5, and Nppa, but loss of Hey2
does not alter the expression of ventricular genes (Koibuchi
and Chin, 2007; Xin et al., 2007). Collectively, these findings
reveal a transcription network that controls a set of marker genes
for atrial/ventricular identity. However, the aforementioned in-
sufficiency of Tbx5, Hey2, and Irx4 in directing major atrial/ven-
tricular gene expression also suggests that an additional major
regulator(s), yet to be identified, is responsible for controlling a
large number of atrial and ventricular genes (Bruneau et al.,
2001a, 2001b; Xin et al., 2007) to set up atrial/ventricular identity.
Chicken Ovalbumin Upstream Promoter Transcription Factor
II (COUP-TFII) is an orphan nuclear receptor that belongs to
the steroid receptor superfamily (Tsai and Tsai, 1997). The highly
conserved COUP-TFII controls cell proliferation, differentiation,
and fate determination by modulating transcriptional activities
of a large number of target genes (Lin et al., 2010; Pipao´n
et al., 1999; Qin et al., 2010a, 2010b; Tang et al., 2010, 2012;
Xie et al., 2011; Yu et al., 2012). In the cardiovascular system,
COUP-TFII is expressed in the venous/lymphatic endothelium,
vascular smooth muscle cells, endocardium, and epicardium
(Lin et al., 2010, 2011; Pereira et al., 1999; You et al., 2005).
Most interestingly, we found that COUP-TFII is expressed in
atrial cardiomyocytes, but not in the ventricular myocardium
(Lin et al., 2012). Further, germline deletion of COUP-TFII results
in defective vascular remodeling and heart development (Pereiralopmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc. 417
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Figure 1. Morphology of the Ventricularized
Atria
(A–J) Hearts of 2-month-old adult mice staining for
MLC2a and MLC2v in denoted genotypes. He-
matoxylin was utilized for counterstaining. Scale
bars represent 500 mm. la, left atria; lv, left ventri-
cles; ra, right atria; rv, right ventricles.
(K and L) Bar graphs showing mean length (K) and
width (L) of isolated cardiomyocytes. Error bars
denote standard error of the mean. ***p < 0.001.
(M–O) Confocal fluorescent images of represen-
tative di-8-ANEPPS-stained myocytes with geno-
types denoted on the side.
(P) Index of the spatial integrity of T tubules (TT
power). Each genotype was composed of three
animals at 2 months of age. Error bars denote
standard error of the mean. ***p < 0.001.
See also Figure S1.
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COUP-TFII and Atrial Identityet al., 1999), and conditional ablation ofCOUP-TFII in endothelial
cells determines that COUP-TFII confers vein identity by sup-
pressing Notch signaling in the venous endothelium (Chen
et al., 2012; You et al., 2005). The specificCOUP-TFII expression
pattern in the atrial myocardium prompted us to investigate the
role of COUP-TFII in the specification of atrial identity.
Based on our understanding of COUP-TFII’s role in cell-fate
determination and its atrial-specific expression pattern, we hy-
pothesized that COUP-TFII determines atrial identity through
regulation of genes necessary for conferring atrial/ventricular
characteristics. In the present study, by in vivo manipulation of
COUP-TFII levels in developing cardiomyocytes, we show that
COUP-TFII is necessary and sufficient to confer atrial identity.
Our data further show that COUP-TFII regulates the expression
of a wide spectrum and a large number of differentially ex-
pressed genes between atria and ventricles, including known
transcription regulators Tbx5, Hey2, and Irx4. Moreover, chro-
matin immunoprecipitation (ChIP) assays and subsequent
sequencing analysis reveal thatmanyCOUP-TFII potential target
genes are associated with cardiac development and physiology.
Taken together, the present work demonstrates that COUP-TFII
is a major regulator determining atrial identity during cardiac
development.
RESULTS
Ablation of COUP-TFII in the Myocardium
Ventricularizes the Atrium
To specifically dissect the role of COUP-TFII in the developing
myocardium, the COUP-TFII flox allele was crossed with
Myh6-cremice to generatemyocardial-specificCOUP-TFII-defi-
cient (CKO) mice. Diminished COUP-TFII protein levels were first
observed in the myocardium of free wall regions in embryonic
day (E)9.5 CKO atria (CKOA) (Figures S1A–S1G available online),
whereas its expression in endocardial cells remained the same418 Developmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc.(Figures S1D–S1G). Importantly, COUP-
TFII protein levels in the Isl1-demarcated
zone of progenitors and the adjacent
newly differentiated a smooth muscle
actin-positive cardiomyocytes remainedcomparable between control and CKO mice (Figures S1H–
S1S). By E10.5, COUP-TFII is absent in most CKO myocytes
(Figures S1T–S1Y). Deletion of the COUP-TFII gene was further
confirmed by expression of recombinant b-galactosidase (Fig-
ures S1C and S1Z), which is activated only upon successful
recombination (Takamoto et al., 2005). These findings indicate
that COUP-TFII was efficiently deleted in cardiomyocytes of
CKO mice.
The resulting adult CKO atria showed a gain of expression of
the ventricular marker Myl2 (MLC2v) in both sides of the atria
(Figures 1A, 1B, 1D, and 1E; Figures S1AB and S1AC), but a
loss of expression of the atrial markers MLC2a and Gja5 (Figures
1C and 1F; Figures S1AA, S1AC, and S1AD). In addition, the size
of the CKO atria is significantly larger than the atria of control
mice (Figures 1A and 1D). A similar phenotype was also
observed in the SM22-cre-mediated myocardial COUP-TFII
deletion mutant (CKOSM22-cre) mice that exhibited gain of
MLC2v, loss of MLC2a, and an increase in atrial size (Figures
1G–1J). The fact that ventricularized atria are observed in two in-
dependent models strongly suggests an indispensable role of
COUP-TFII in determining atrial identity.
To examine the morphological and structural alterations in
COUP-TFII-deficient cardiomyocytes, we isolated individual car-
diomyocytes from adult atria and ventricles. We found that atrial
CKOA myocytes were significantly longer than myocytes from
control atria (CTRLA), reaching the length of ventricular (CTRLV)
myocytes of wild-type control mice (Figure 1K; Figures S1AE–
S1AH). Also, the width of the mutant atrial myocytes was thicker
than the width of control cells (Figure 1L; Figures S1AE–S1AH).
In small mammals, a distinct feature of adult ventricular myo-
cytes is the T tubule system that is an extension of narrow and
inward projection of sarcolemma, which is not commonly
observed in the atrium (Orchard and Brette, 2008; Smyrnias
et al., 2010). In contrast to the absence of fully developed T
tubules in CTRLA myocytes (Figure 1M), CKOA myocytes
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Figure 2. Molecular Profile of Ventricularized Atria in CKO Hearts
(A) Venn diagram to compare genes upregulated in CKO atria (black circle) and
ventricular genes (gray circle).
(B) Venn diagram to compare genes downregulated in CKO atria (black circle)
and atrial genes (gray circle).
(C–H) Relative mRNA levels of marker genes in adult atria (n = 4 for each ge-
notype). Error bars denote standard error of the mean. ***p < 0.001.
See also Tables S1, S2, and S3.
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Figure 3. Electrical Properties of Adult CKO Myocytes and Hearts
(A–C) Representative diagrams of action potential recording from isolated
CTRLA (A), CKOA (B), and CTRLV (C) myocytes.
(D) Mean action potential durations of isolated cardiomyocytes at APD90. N
(number of cells) = 15 for CTRLA, 15 for CKOA, and 7 for CTRLV within each
bar from three animals per group. Error bars denote standard error of the
mean. ***p < 0.001.
(E and F) Representative surface and intra-atrial electrocardiogram during
programmed induction of AF in CTRL (E) and CKO (F) mice.
See also Figure S2 and Tables S4 and S5.
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COUP-TFII and Atrial Identitydisplayed organized T tubules that crossed and extended deep
into the cells (Figure 1N), similar to CTRLVmyocytes (Figure 1O).
Quantitative analysis of the spatial integrity of T tubules, repre-
sented by the TT power index, further confirmed the increase
of T tubule development in CKOA myocytes (Figure 1P). These
morphological assessments together indicate that myocardial
deletion of COUP-TFII allows the atrial myocytes to acquire ven-
tricular cellular morphology.
Alteration in the Molecular Profile of COUP-TFII-
Depleted Atria
To gain insight into the molecular changes displayed by the ven-
tricularized CKO atria, we performed gene expression profiling
on CKOA, CTRLA, and CTRLV tissues using microarray analysis
(Figures 2A and 2B; Table S1). Expression profiling between
CTRLA and CTRLV identified 2,099 and 2,520 genes preferen-
tially expressed in ventricles (ventricular genes) and atria (atrial
genes), respectively (gray circles in Figures 2A and 2B), whereas
COUP-TFII ablation resulted in 1,123 up- and 1,461 downregu-
lated genes in CKOA in comparison to the CTRLA (black circles
in Figures 2A and 2B). Among the COUP-TFII-regulated genes,
75% (837 out of 1,123) of upregulated genes belonged to ven-
tricular genes and 86% (1,258 out of 1,461) of downregulated
genes were atrial genes. Together, COUP-TFII controlled
45.4% (2,095 out of 4,619) of genes that were differentially ex-
pressed between the atria and ventricles. Transcript levels
measured by quantitative PCR (qPCR) further confirm the results
of microarray analysis, in which myocardial ablation of COUP-
TFII caused increased expression of the ventricular marker
genes Myl3 (MLC1v) and Phospholamban (Pln) (Figures 2D and
2E) and decreased expression of the atrial marker genes
MLC1a, Sln, and Gja5 (Figures 2F–2H) (Babu et al., 2007; Xin
et al., 2007). These changes in gene expression indicate that
the main function of COUP-TFII in the myocardium is to promote
atrial and suppress ventricular gene expression.DeveFunctional classification of the atrial/ventricular genes re-
vealed that COUP-TFII controls a wide range of molecular func-
tions (Table S2). Further analysis of these genes in the category
of cellular components indicated that genes associated with
mitochondria and the endoplasmic reticulum/Golgi apparatus
were overrepresented in both up- and downregulated genes,
respectively (Table S3). In the category of biological processes,
terms associated with energy production are overrepresented
in the group of upregulated genes, whereas many downregu-
lated genes are associated with protein/vesicle transportation.
The altered genes in CKOA correspond to the unique neurohor-
monal character of atria and efficient energy production appa-
ratus of the ventricles (Barth et al., 2005; McGrath and de
Bold, 2009; Tabibiazar et al., 2003). Together, our results demon-
strate that the main function of COUP-TFII in the myocardium is
to confer atrial identity by promoting atrial and suppressing ven-
tricular gene expression in a broad range of gene targets.
COUP-TFII-Deficient Atrial Myocytes Exhibit Ventricular
Electrical Activities
Our gene expression analyses identified a ventricularized expres-
sion pattern ofmany ion-channel genes inCKOAmyocytes (Table
S4). This altered molecular pattern and the development of orga-
nized T tubules together suggest that COUP-TFII-deficient atrial
myocytes may also exhibit ventricularized electrical activities.
To investigate thispossibility,weperformedpatch-clampanalysis
to measure action potentials on isolated adult cardiomyocytes.
In control mice, the atrial action potential had a triangular
shape (Figure 3A), whereas the ventricular action potential con-
tained a more pronounced plateau phase with a longer action
potential duration at 90% recovery of depolarization (APD90)
(Figures 3C and 3D; Figure S2A). Strikingly, the action potentiallopmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc. 419
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Figure 4. Temporal Analysis of Identity
Switch
(A–H) Heart regions of CKO and control mice
stained for MLC2v with age denoted on the side.
(I) qRT-PCR for MLC2v mRNA levels in atria from
E9.5 to 2-month-old adult mice. Fold changes of
CKO are normalized to the corresponding control
at the same age. Asterisks denote significant dif-
ferences between genotypes of the same age.
Error bars denote standard error of the mean.
***p < 0.001.
(J–M) Heart regions at E18.5 of CKOMyh6-MCM and
corresponding control mice stained for MLC2v.
E18.5TamE12.5 and E18.5TamE15.5 embryos
received tamoxifen at E12.5 and E15.5, respec-
tively. Insets in (K) and (M) show double staining of
MLC2v (red) andb-gal (green)withDAPI for nucleus
staining on an adjacent section of (K) and (M),
respectively. Hematoxylin was utilized for counter-
staining in all sections except insets in (K) and(M).
See also Figure S3.
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COUP-TFII and Atrial Identityof CKOA myocytes exhibited a pronounced plateau phase and
had comparable APD90 to the CTRLV myocytes (Figures 3B
and 3D; Figure S2A). This altered pattern of action potential indi-
cates that CKOA myocytes gained functional electrical charac-
teristics of ventricular myocytes.
To examine whether the ventricularized atria still possess atrial
electrical characteristics, adult hearts were subjected to a stress
test using rapid pacing to induce atrial fibrillation (AF) (Li and
Wehrens, 2010). Whereas 6 out of 11 control mice developed
at least one episode of AF (Figure 3E; Figure S2B), none of the
7 CKO mice developed AF (Figure 3F; Figure S2B). We also
measured the proportion of attempts that resulted in successful
induction of AF and termed it the AF score. Among the control
mice, four mice (36%) had an AF score of 33%, one mouse
(9%) had an AF score of 67%, and one had an AF score of
100%. In contrast, all the CKOmice had an AF score of 0% (Fig-
ure S2C). These results indicate that whereas mice with normal
atria were susceptible to AF induction, the ventricularized CKO
atrial myocardium lost the AF susceptibility as part of atrial elec-
trical characteristics and prevented induction of AF following
programmed electrical stimulation.
To exclude the possibility that a change of AF susceptibility is
secondary to ventricular dysfunction, we performed 2D echocar-
diography on both CKO and control mice to examine ventricular
morphology and pump functions. We found that the ventricle
size and mass, as reflected by left ventricle internal diameter in
diastole (LVID;d) and left ventricular posterior wall thickness in
diastole (LVPWD;d), respectively, were both similar between
the groups (Table S5). The left ventricle pump function measured
as fractional shortening and ejection fraction was also similar be-
tween both groups (Table S5). We thus concluded that the
altered electrical properties in CKO mice were primarily due to
the effect of loss of COUP-TFII in atrial myocardium.420 Developmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc.COUP-TFII Determines Atrial
Identity during Embryonic Heart
Development
The COUP-TFII-dependent identity
switch as revealed by positive immuno-staining of MLC2v in atrial cardiomyocytes can be detected as
early as E10.5 (compare Figure 4Cwith Figure 4D) and continues
to be observed at later stages of embryonic development (Fig-
ures 4E–4H). The temporal increase in mRNA expression of
MLC2v in the mutant atrium as compared to the control atrium
from E9.5 to adult is further confirmed by qRT-PCR analysis (Fig-
ure 4I). Whereas an increase in the expression of ventricular
markers MLC1v and Pln and a reduction in the expression of
atrial markers Sln, Kcnj3, and Gja5 could be easily seen in the
E14.5 CKO atria (Figures S3A–S3E), CKO atria have yet to
achieve a complete ventricular identity change at E14.5, as evi-
denced by the facts that the mutant atria still display the mosaic
MLC2v staining pattern (Figure 4H) and the expression ofMLC2v
mRNA has yet to reach the maximal levels as seen in the adult
(Figure 4I).
To determine whether COUP-TFII is required for the identity
switch at later stages of development, we used an inducible-
Cre (Myh6-MerCreMer) system to ablate COUP-TFII
(CKOMyh6-MCM) in cardiomyocytes at later stages. Tamoxifen
was administered to embryos at E12.5 (E18.5TamE12.5) or
E15.5 (E18.5TamE15.5) to induce COUP-TFII ablation, and car-
diac sections from embryos were then used to examine the
expression of the ventricular marker MLC2v at E18.5 (Figures
4J–4M). It is clear that ablation of COUP-TFII at E12.5 results
in ectopic expression of MLC2v in the mutant atria (Figure 4K).
Using b-gal staining to mark COUP-TFII-ablated cells in atria,
we also found that b-gal-positive cells (green in Figure 4K inset)
often coexpress with the ventricular marker MLC2v (red in Fig-
ure 4K inset) in embryos that received tamoxifen at E12.5 (Fig-
ure 4K). The above results indicate that atrial myocytes can
switch identity when COUP-TFII is deleted at E12.5. In contrast,
both immunopositive MLC2v myocytes and coexpression of
MLC2v (red in Figure 4M inset) and b-gal (green in Figure 4M
A B C D E F G H I
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Figure 5. Regulation of Atrial/Ventricular
Identity Transcription Factors by COUP-TFII
(A–I) Relative mRNA levels of denoted genes from
pooled E14.5 CTRL (solid bar) and CKO (open bar)
atria measured by qPCR. Each group consisted of
two independent pools of atrial samples. Levels
are shown as relative folds over control.
(J–L) ChIP-PCR assays on pooled E13.5 atria using
anti-COUP-TFII antibody (solid bar) or IgG (open
bar). Diagrams on the top indicate COUP-TFII
binding sites. Bar graphs show enrichment of DNA
fragments pulled down by antibodies. N indicates
a region in the Hbb locus without COUP-TFII or
Sp1 binding sites that served as a negative control.
Error bars denote standard error of the mean. *p <
0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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COUP-TFII and Atrial Identityinset) myocytes are no longer seen from atrial cardiomyocytes
when COUP-TFII was ablated at E15.5, indicating that the plas-
ticity of switching identity is lost when COUP-TFII is ablated at
later embryonic stages (Figure 4M). In addition, no apparent
alteration of atrial size was observed in mice with COUP-TFII
deletion after E15.5 (data not shown), suggesting that the atrial
enlargement phenotype is only observed in COUP-TFII deletion
prior to E15.5. Collectively, these results suggest thatCOUP-TFII
is required for the specification of atrial cardiomyocyte identity at
early stages of development, but not for maintenance of the
identity when atrial fate is already determined.
COUP-TFII Directly Regulates Expression of Genes for
Atrial/Ventricular Identities
Cardiac morphogenesis requires coordination of multiple tran-
scription factors to control differentially expressed genes in
each individual compartment (Evans et al., 2010; Small and
Krieg, 2004). We next examined whether and to what extent
the expression of cardiac transcription factors were affected in
E14.5 CKO atria. Expression levels of Tbx5 and Hey1, two tran-
scription factors preferentially expressed in the atrial compart-
ment (Bruneau et al., 2001b; Leimeister et al., 1999; Nakagawa
et al., 1999), decreased subsequent to COUP-TFII deletion (Fig-
ures 5A–5C). In contrast, the expression of Hey2, Irx4, and Lbh
transcription factors that are restrictively expressed in ventricles
(Briegel and Joyner, 2001; Bruneau et al., 2000; Koibuchi and
Chin, 2007; Nakagawa et al., 1999) significantly increased in
CKO atria (Figures 5D–5F), whereas the expression of general
cardiac transcription factors Tbx20,Nkx2.5, andGata4 remained
unchanged (Figures 5G–5I) (Kraus et al., 2001; Nemer and
Nemer, 2002; Tanaka et al., 1999).
Reduction of Tbx5 mRNA in E14.5 COUP-TFII mutant atria
suggests that COUP-TFII promotes Tbx5 expression. Others
and we have shown previously (Chen et al., 2012; Kim et al.,
2009; Pipao´n et al., 1999; Qin et al., 2010a; Rohr et al., 1997;
Tang et al., 2010, 2012; Yu et al., 2012) that COUP-TFII positively
regulates its target gene expression through tethering to the Sp1
factor at Sp1 binding sites. To identify Sp1 binding sites in theDevelopmental Cell 25, 417–Tbx5 locus, we used ECR Browser/mul-
tiTF software from the National Center
for Biotechnology Information (NCBI;
http://www.dcode.org) and found threepotential Sp1 sites in the evolutionarily conserved regions (Fig-
ure S4A). ChIP-qPCR assays found binding of COUP-TFII at
sites 1 and 2 (Figure 5J), whereas no enhanced COUP-TFII
recruitment was found in site 3 (data not shown). To test the func-
tionality of identified Sp1 binding sites, a 2 kb Tbx5 upstream
sequence that harbors the 6.3 kb Sp1 site (site 1) was cloned
and placed in front of an SV40 promoter driven-luciferase re-
porter (Figure S4B). Results of luciferase assays, performed in
HL-1 atrial cardiomyocytes, showed that this sequence
enhanced luciferase reporter activities and that the enhance-
ment was greatly reduced upon deletion of the Sp1 site (Fig-
ure S4B). Taken together, the results indicate that the region
containing the Sp1 binding site can mediate COUP-TFII-depen-
dent Tbx5 expression.
Quantitative PCR analysis also suggests that COUP-TFII sup-
presses Hey2 and Irx4 expression (Figures 5D and 5E). We
showed previously that COUP-TFII represses its target gene
expression through direct binding to the COUP-TFII response el-
ements, a direct repeat (DR) of AGGTCA sequences with
different spacing between the half-sites (Tsai and Tsai, 1997).
Based on previously identified COUP-TFII binding motifs (Chen
et al., 2012; Qin et al., 2010b; Tang et al., 2010; Tsai and Tsai,
1997; Xie et al., 2011), we deduced a consensus sequence
and used it to identify candidate COUP-TFII binding sites in the
evolutionarily conserved regions listed in the phastConsEle-
ments30way table of the UCSC Genome Browser (http://www.
genome.ucsc.edu). We found ten regions that harbor potential
COUP-TFII-binding motifs with variable homology to the
consensus sequences in the Hey2 genomic locus (marked blue
regions in Figure S4C). ChIP-qPCR assays found COUP-TFII
binding only at sites 1 and 2 (Figure 5K; Figure S4C), whereas
no enhanced COUP-TFII recruitment was found in other regions
with less homology to the consensus sequences (other blue re-
gions in Figure S4C). This finding confirms our previous observa-
tion that COUP-TFII suppresses Hey2 expression in human um-
bilical vein endothelial cells (Chen et al., 2012), supporting the
notion that COUP-TFII utilizes a similar mechanism to regulate
Hey2 expression in cardiomyocytes. Using the same approach,426, May 28, 2013 ª2013 Elsevier Inc. 421
*** 
*** *** 
0 
20 
40 
60 
MLC2v 
0 
0.5 
1 
MLC2a 
0 
0.5 
1 
MLC1a 
B D C 
0 
0.5 
1 
1.5 
Id2 
0 
3 
6 
9 
Kcne1 
*** * 
E F 
CTRL 
CKO 
*** 
G 
0 
0.5 
1 
1.5 
Fgf1 
Category Term p Value 
GOTERM_BP_FAT GO:0007507~heart development 2.8 x 10-9 
KEGG_PATHWAY mmu05414:Dilated cardiomyopathy 1.2 x 10-7 
KEGG_PATHWAY mmu05410:Hypertrophic cardiomyopathy (HCM) 1.2 x 10-5 
GOTERM_BP_FAT GO:0048738~cardiac muscle tissue development 3.6 x 10-4 
GOTERM_BP_FAT GO:0008016~regulation of heart contraction 5.3 x 10-4 
KEGG_PATHWAY mmu05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
2.8 x 10-3 
GOTERM_BP_FAT GO:0042692~muscle cell differentiation 3.3 x 10-3 
GOTERM_CC_FAT GO:0044449~contractile fiber part 2.2 x 10-7 
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Figure 6. Identification of Global COUP-
TFII-Binding Targets in Atria
(A) Enriched functional annotation terms by DAVID
Bioinformatics Sources (http://david.abcc.ncifcrf.
gov) from ChIP-seq-identified genes that contain
COUP-TFII binding sites in E13.5 atria.
(B–G) Expression levels of denoted genes in E14.5
CKOatriacomparedwithcontrol.Errorbarsdenote
standard error of the mean. *p < 0.05; ***p < 0.001.
(H) ChIP-seq result of COUP-TFII binding in the
MLC2v (Myl2) locus. COUP-TFII-binding motifs
are shown in capital letters in boxes.
(I) ChIP-qPCR results on pooled E13.5 atria using
anti-COUP-TFII antibody (solid bar) or IgG (open
bar). Bar graphs show enrichment of DNA frag-
ments pulled down by antibodies. N indicates a
region in the Hbb locus without COUP-TFII bind-
ing sites that served as a negative control. Error
bars denote standard error of the mean. *p < 0.05;
**p < 0.01.
See also Figure S5 and Table S6.
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COUP-TFII and Atrial Identitywe found that COUP-TFII is recruited to sites 1 and 2 among the
five conserved regions identified in the Irx4 genomic locus (Fig-
ure 5L; Figure S4D). Taken together, our results suggest that
COUP-TFII represses Hey2 and Irx4 gene expression in cardio-
myocytes via direct binding to COUP-TFII response elements
at the Hey2 and Irx4 genomic loci.
To globally identify potential COUP-TFII direct targets, we
immunoprecipitated E13.5 atrial chromatin, and the subsequent
deep sequencing identified 2,863 COUP-TFII binding sites;
5,982 genes were found to have COUP-TFII binding sites within
50 kb of their gene margins. Functional annotation analysis of
these genes revealed enrichments for cardiac morphogenesis,
heart physiology, and cardiomyopathy (Figure 6A; Table S6),
suggesting that COUP-TFII directly regulates expression of
numerous genes involved in heart development and function.
Notably, COUP-TFII binds to genomic loci of classic atrial-ven-
tricular identity genes MLC2v, MLC2a, MLC1a, and Irx4 (Bru-
neau et al., 2000; Xin et al., 2007) andmodulates their expression
(Figures 5E and 6B–6D), supporting that COUP-TFII directly reg-
ulates these atrial/ventricular identity genes at the time when
COUP-TFII confers atrial identity. In addition to genes important
for atrial specification, COUP-TFII also binds to and controls the
expression of many genes that participate in various aspects of
cardiac function, such as Kcne1, a voltage-gated potassium
channel, Id2, a cardiac transcription factor, and Fgf1, a growth422 Developmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc.factor (Figures 6E–6G). Therefore, our re-
sults show that COUP-TFII confers atrial
identity through direct binding to pro-
moter/enhancer regions to modulate the
expression of a broad spectrum of genes
that play key roles in atrial development
and function.
To test the functionality of the identified
COUP-TFII binding sites, we took advan-
tage of a defined MLC2v enhancer, the
mm77 regulatory sequence located up-
stream of theMLC2v gene, that was pre-
viously validated in vivo for recapitulatingthe endogenous MLC2v expression pattern (Blow et al., 2010).
ChIP-seq identified one binding site that has a DR2 COUP-
TFII-binding motif within its regulatory sequence (site 1 in Fig-
ure 6H), which we confirmed by ChIP-qPCR (site 1 in Figure 6I).
In addition to this site, ChIP-qPCR also identified a COUP-TFII-
binding region that contained a DR0 motif sequence (site 2 in
Figures 6H and 6I). This second COUP-TFII binding site was
not detected by ChIP-seq analysis, which may be due to the
different sensitivities of the detection methods we used. Indeed,
ChIP-qPCR analysis showed that the recruitment of COUP-TFII
to both sites is significantly biased for the site identified by ChIP-
seq (Figure 6I). Luciferase reporter assays in HL-1 atrial cardio-
myocytes revealed that either one site alone is sufficient to
suppress reporter activity (Figure S5A), indicating that COUP-
TFII represses MLC2v gene expression through binding to mul-
tiple chromatin sites. These results confirm our previous findings
that COUP-TFII can repress target gene expression through
direct binding to DR COUP-TF response elements to negatively
regulate transcription (Chen et al., 2012; Qin et al., 2010b; Tang
et al., 2010; Tsai and Tsai, 1997; Xie et al., 2011).
Atrialization of Ventricular Cardiomyocytes by Ectopic
COUP-TFII Expression
Loss-of-function studies indicated that COUP-TFII is essential
to determine atrial cardiomyocyte identity. To confirm that
C
TR
L 
O
E 
MLC2a MLC2v 
C
O
U
P-
TF
II 
A 
C 
B 
D 
E F 
G
*** 
H 
*** 
I 
** 
Figure 7. Atrialized Ventricular Myocytes by COUP-TFII Over-
expression
(A–D) Adjacent coronal sections of E17.5 control (A and B) and COUP-TFII
overexpression (C and D) hearts stained for MLC2a (A and C) and MLC2v (B
and D).
(E and F) High-power view of adjacent sections corresponding to areas boxed
in (C) and (D) that are double stained for COUP-TFII (green) with MLC2a (E) or
MLC2v (F) in red. Nuclei were stained in blue by DAPI.
(G–I) Relative mRNA levels of Tbx5 (G), Hey2 (H), and Irx4 (I) from E17.5 CTRL
(black bar) and COUP-TFII overexpression (gray bar) ventricles measured by
qRT-PCR. Each group consisted of three individual ventricles. Levels are
shown as relative folds over control. Error bars denote standard error of the
mean. **p < 0.01; ***p < 0.001.
Developmental Cell
COUP-TFII and Atrial IdentityCOUP-TFII is sufficient to confer atrial identity, we ectopically
expressed COUP-TFII in ventricular myocardium by using an
SM22-cre-mediated COUP-TFII overexpression (OE) system
(Qin et al., 2013; Wu et al., 2010). The mosaicism produced by
the transient SM22-cre expression in myocardium provided an
advantage in comparing COUP-TFII-expressing and -nonex-
pressing cells side by side. At E17.5, a subpopulation of OE ven-
tricular cardiomyocytes expressed the atrial marker MLC2a
instead of the ventricularmarkerMLC2v (Figures 7A–7D). Double
immunostaining showed that MLC2a-positive myocytes were
only colocalized with COUP-TFII (Figure 7E), whereas other
MLC2v-expressing myocytes did not show COUP-TFII expres-
sion (Figure 7F). Moreover, compared with the control, COUP-
TFII-overexpressing ventricles exhibited increased levels of
Tbx5 for atrial gene expression and decreased Hey2 and Irx4
levels that promote ventricular gene expression (Figures 7G–7I).DeveCollectively, our results demonstrate thatCOUP-TFII is sufficient
to confer atrial identity in a cell-autonomous manner.
Increased Proliferation in COUP-TFII-Deficient
Cardiomyocytes
The increase in CKO atrial chamber size is first apparent at E14.5
(Figures S3F and S3G). To determine whether cardiomyocyte
proliferation contributes to the atrial enlargement, we examined
mitogenic activities by counting phosphohistone H3-positive,
Nkx2.5-positive cardiomyocytes in E12.5 atria. Mutant atria
contained a significantly higher number of phosphohistone H3-
positive, Nkx2.5-positive cells (Figure S3H), suggesting that an
increase in myocyte proliferation contributes to the increase of
atrial chamber size. Interestingly, mutant atrial cardiomyocytes
exhibit a slightly but significantly smaller estimated cell size
compared with the control (Figure S3J) at both E14.5 and
E16.5. Our data suggest that increased myocyte proliferation
serves as the primary cause of enlarged atrial size during embry-
onic development, whereas the increase in cell size occurs after
E16.5.
DISCUSSION
Previous work by others has shown that atrial and ventricular
myocytes are originated from different sets of cardiac progenitor
cells preallocated at specific anatomical positions. Yet, it is un-
clear at which stage the atrial/ventricular identities are deter-
mined. Using two independent myocardial-restrictive Cre lines,
the Myh6-cre and SM22-cre, to abate COUP-TFII, we show
that atrial/ventricular identities can be switched in differentiating
cardiomyocytes. The temporal study using Myh6-MerCreMer
mice as the Cre driver further reveals that the plasticity of identity
switch remains subsequent to initial cardiomyocyte differentia-
tion but is lost at later embryonic stages. These results suggest
that differentiating cardiomyocytes have the plasticity of chang-
ing identity. Our results also demonstrate that ablation of COUP-
TFII in cardiomyocytes is sufficient to produce ventricularized
atria in which myocytes increase in size, develop organized T
tubules, acquire ventricular electrical properties, and exhibit a
molecular profile resembling ventricular myocytes. These struc-
tural, electrical, and molecular alterations strongly suggest that
the mutant atrial myocyte switched its identity from atria to
ventricles.
Based on our results, COUP-TFII could be considered as a
key component within the regulatory network that determines
atrial-ventricular identity. In this network, Tbx5 is known to be
essential for atrial development and promotes expression of
several atrial genes (Bruneau et al., 2001b). However, its ven-
tricular expression and propensity to promote ventricular
gene expression and morphogenesis reduce its merit as a spe-
cific determinant of atrial identity (Bruneau et al., 2001b; Mori
et al., 2006). In contrast, myocardial COUP-TFII expression is
strictly restricted to the atria, rendering it capable of promoting
atrial genes while suppressing ventricular gene expression. As
expected, myocardial ablation of COUP-TFII only affects atrial
specification without obvious impacts on ventricular
morphology and function, indicating that COUP-TFII is a critical
factor in conferring atrial identity. On the other hand, spec-
ification of ventricles requires promoting ventricular andlopmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inc. 423
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COUP-TFII and Atrial Identitysuppressing atrial genes. Ventricular Hey2 has been shown to
suppress several atrial genes including MLC1a, MLC2a, Sln,
Gja5, and Nppa, but has no effect on the expression of ventric-
ular genes such as MLC1v, MLC2v, and Pln (Koibuchi and
Chin, 2007; Xin et al., 2007). These findings suggest that
Hey2 is required but not sufficient to confer ventricular identity.
Irx4 also promotes ventricular Hand1 and Hand2 and sup-
presses atrial reporter SmyHC3-HAP expression (Bao et al.,
1999; Bruneau et al., 2001a), yet it does not regulate many
atrial/ventricular marker genes such as MLC1a, MLC2a,
MLC1v, and MLC2v (Bruneau et al., 2001a). Interestingly, Irx4
ablation does not affect ventricular formation, indicating that
it is not essential for atrial/ventricular specification during em-
bryonic development (Bruneau et al., 2001a). In contrast,
COUP-TFII is both sufficient and necessary in conferring atrial
while suppressing ventricular characteristics. Thus, COUP-
TFII is the only factor that is currently known to be essential
and sufficient in determining atrial/ventricular identity.
Based on our findings, COUP-TFII confers atrial identity
through direct regulation of a broad spectrum of genes that
play roles in atrial development and function. In addition to
the known transcription regulators Tbx5, Hey2, and Irx4,
silencing Id2 expression may also be a way for COUP-TFII to
confer atrial identity. In the heart, a group of specialized cardi-
omyocytes that are functionally distinct from atrial and ventric-
ular myocytes forms the cardiac conduction system (Chien
et al., 2008). It has been shown that Id2 is prominently ex-
pressed in the ventricular conduction system, including the
atrioventricular bundle and the bundle branches, and is
required for the development of the ventricular conduction sys-
tem (Moskowitz et al., 2007). However, Id2 is largely absent in
atrial myocardium (Jongbloed et al., 2011; Moskowitz et al.,
2007). Our ChIP-seq and qRT-PCR results suggest a direct
repression role of COUP-TFII on the expression of Id2 (Fig-
ure 6F). Thus, it is possible that COUP-TFII directly suppresses
Id2 expression to prevent abnormal development of ventricular
conduction systems in the atria, which would be another means
to establish atrial identity. Further studies are needed to test
this hypothesis.
Results from our ChIP-seq assay also implicate that COUP-
TFII may regulate cell differentiation through the histone deace-
tylase-myocyte enhancer factor 2 (HDAC-MEF2) pathway.
COUP-TFII binding sites are found in genomic loci of Hdac9,
Mef2d, and Camk2d. MEF2 transcription factors have been
shown to be critical for regulation of differentiation in the heart
(Potthoff and Olson, 2007). In addition, emerging evidence indi-
cates the capacity ofHdac9,Mef2d, andCamk2d to control cell-
fate decision (Della Gaspera et al., 2012; Sagasti et al., 2001; Tao
et al., 2007). These results implicate potential functional interac-
tions between COUP-TFII, Mef2d, Hdac9, and Camk2d during
heart development. Furthermore, we also found COUP-TFII
binding sites in genomic loci of many genes in the calcium
signaling pathway (Figure S5B), an important pathway that trans-
duces signals into the HDAC-MEF2 pathway to regulate heart
development (Potthoff and Olson, 2007). Whether calcium
signaling, HDAC-MEF2, and COUP-TFII act jointly to specify
atrial-fate decision awaits future experimentation.
Our results indicate that COUP-TFII may directly modulate
expression of many genes that encode immediate physiological424 Developmental Cell 25, 417–426, May 28, 2013 ª2013 Elsevier Inregulators for atrial function (Table S6). The importance of direct
regulation of expression of physiological regulators is exempli-
fied by the regulation of the MLC2v gene by COUP-TFII.
MLC2v is not only a classic ventricular identity gene but also en-
codes an essential component in muscle fibers. Simple ectopic
expression of theMLC2v gene in atria can reduce protein levels
ofMLC2a, the atrial-specific form ofmyosin light chain, with sub-
sequent changes in mechanical properties of transgenic atrial
myocytes to a level similar to that of ventricular myocytes
(Buck et al., 1999; Pawloski-Dahm et al., 1998). Therefore,
silencing the MLC2v gene in atrial myocytes is critical for main-
taining correct atrial mechanical properties, and we show that
COUP-TFII directly suppresses transcriptional activities of the
MLC2v gene to ensure the establishment of atrial identity (Fig-
ure 6B). This further demonstrates that COUP-TFII confers atrial
identity via direct control of genes that have a critical impact on
atrial function.
Among the 837 COUP-TFII-regulated ventricular genes that
are overexpressed in mutant atria, 286 genes (34%) contain
COUP-TFII binding sites in the promoter or enhancer of the
gene loci. On the other hand, among the 1,258 COUP-TFII-regu-
lated atrial genes that exhibit underexpression in mutant atria,
389 genes (31%) harbor COUP-TFII binding sites in their gene
loci. Together, these 675 genes constitute 32% of the COUP-
TFII-regulated atrial/ventricular genes. Our finding suggests
that COUP-TFII may control the atrial/ventricular gene expres-
sion pattern through direct and indirect actions of COUP-TFII.EXPERIMENTAL PROCEDURES
Mice
Mice carrying the COUP-TFII null, COUP-TFII flox, and CAG-S-COUP-TFII
allele were described previously (Pereira et al., 1999; Qin et al., 2013; Taka-
moto et al., 2005). Myh6-cre (Agah et al., 1997), SM22-cre (Boucher et al.,
2003), and Myh6-MerCreMer mice (Sohal et al., 2001) were acquired from
the Jackson Laboratory (stocks 011038, 004746, and 005650, respectively).
All animal experiments adhered to guidelines of the Institutional Animal Care
and Use Committee of the Baylor College of Medicine and were conducted
within the scope of approved animal protocols.
Expression Array Analysis
Cardiac tissues were collected from 2-month-old animals. The control
atria group consisted of three pools of right atria, six atria per pool from
COUP-TFIIflox/flox mice, whereas the mutant atria group was made up of three
individual right atria fromMyh6-cre; COUP-TFIIflox/floxmice. The control ventri-
cles were collected from three individual whole ventricles of COUP-TFIIflox/flox
mice. Affymetrix mouse genome 430 2.0 chips were used in this study. The
NCBI accession number for the expression array study reported in this paper
is GSE46498.
Electrocardiogram and Echocardiogram
Transthoracic echocardiography, electrocardiogram, and programmed elec-
trical stimulation on mice were performed as described previously (Li and
Wehrens, 2010; Respress and Wehrens, 2010; van Oort et al., 2010). Detailed
information is included in the Supplemental Experimental Procedures.
Ventricular and Atrial Cell Action Potential Recordings
Current clamp recordings were performed using a conventional whole-cell-
mode patch clamp as described previously (Hamill et al., 1981). Detailed infor-
mation can be found in the Supplemental Experimental Procedures. APDs
were determined at different repolarization levels, with full repolarization
defined as 100%.c.
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COUP-TFII and Atrial IdentityT Tubule Imaging and Analysis
T tubules of cardiomyocytes were visualized by di-8-aminoaphthylethenylpyr-
idinium (di-8-ANEPPS) staining. More information is included in the Supple-
mental Experimental Procedures.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation analysis on fresh cardiac tissues was per-
formed according to a previously described method (Lee et al., 2006). Chro-
matin-DNA complexes were collected from E13.5 atria of 50 mouse embryos.
Mouse monoclonal anti-COUP-TFII (R&D Systems; PP-H7147-00) and normal
mouse IgG (Millipore; 12-371) were used for the ChIP assay. DNA released
from the precipitation was subjected to qPCR analysis for quantification of
the presence of specific loci. Primer sequences can be found in Supplemental
Experimental Procedures.
ChIP-Seq
A pool of atrial tissues from 57 E13.5 C57BL/6J mouse embryos snap-frozen
immediately after harvest was sent to ActiveMotif for ChIP, library preparation,
sequencing, and initial data analysis. A rabbit anti-NR2F2 polyclonal antibody
(Active Motif; 61214) was used for ChIP-seq. Peak calling was done with
MACS 1.4.2 (http://liulab.dfci.harvard.edu/MACS) with a cutoff p value set at
105 and produced a false discovery rate of 1.78%. Gene calling was based
on the presence of COUP-TFII binding sites within 50 kb of the gene margin.
The NCBI accession number for the ChIP-seq study reported in this paper is
GSE46498.
ACCESSION NUMBERS
The NCBI accession number for the studies reported in this paper is
GSE46498.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2013.04.017.
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